Detection of hypo-N-glycosylation using mass spectrometry of transferrin.

John F. O'Brien, Jean M. Lacey, H. Robert Bergen

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Many congenital disorders of glycosylation (CDG) can be diagnosed by observing the extent of glycosylation of the abundant serum glycoprotein transferrin (Trf). Trf is an N-glycosylated protein with two asparagine glycation sites. CDG types I are those genetic defects which occur prior to transfer of the complex oligosaccharide to the acceptor asparagine in the cotranslated polypeptide chain. CDG Ia constitutes by far the most frequent form of CDG and is the result of mutations in the phosphomannomutase gene. CDG Ia and the Ib subtype (Phosphomannoisomerase deficiency) result in low cellular mannose-1-phosphate levels, a required precursor for oligosaccharide assembly in the endoplasmic reticulum. The deficiency in oligosaccharides with branched mannose structures is thereafter expressed by the appearance of glycoproteins with unoccupied N-glycosylation sites (hypoglycosylation). Currently, there have been at least 11 Type I defects, type Ia being by far the most frequently occurring. Most, if not all type I defects result in unoccupied N-glycation sites. Hypoglycosylated Trf, also known as carbohydrate-deficient Trf (CDT), can be detected using mass spectrometry (MS) to measure the masses of the serum Trf. The methods for sample preparation using affinity chromatography and MS analysis are described in this unit.

Original languageEnglish (US)
Pages (from-to)Unit 17.4
JournalCurrent protocols in human genetics / editorial board, Jonathan L. Haines ... [et al.]
VolumeChapter 17
DOIs
StatePublished - Jul 2007

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Fingerprint Dive into the research topics of 'Detection of hypo-N-glycosylation using mass spectrometry of transferrin.'. Together they form a unique fingerprint.

  • Cite this